Anbogen and University of Tokyo Collaborate on ABT-301

AnBogen Therapeutics Inc. (TPEx: 7784), a Taiwan-based clinical-stage precision oncology company, announced on August 24, 2026 that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo. The collaboration aims to evaluate ABT-301 (Imofinostat), Anbogen's selective Class I histone deacetylase inhibitor (HDACi), across multiple solid tumor types including osteosarcoma, melanoma, soft tissue sarcoma, bladder cancers, and other refractory solid tumors using established veterinary oncology models. The research will be led by Lecturer Daiki Kato, Professor Takayuki Nakagawa, and Professor Manabu Mochizuki, Director of the Affiliated Veterinary Medical Center. The primary strategic objective is to generate scientific evidence to support the expansion of ABT-301's human clinical indications and optimize combination strategies ahead of future clinical trials. Naturally occurring cancers in dogs are considered clinically and molecularly analogous to human cancers, with canine osteosarcoma being a well-studied comparative oncology model. The collaboration will evaluate ABT-301 as monotherapy and in combination with other agents, with comprehensive mechanistic analyses. ABT-301 is currently in a Phase I/II clinical trial for metastatic colorectal cancer in combination with anti-PD-1 and anti-VEGF. The company believes the mechanism of action has broad applicability across immunotherapy-resistant solid tumors. This partnership is expected to generate translational data to support indication expansion and future clinical development decisions.